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Anti-infective drug development depends
to a great extent on enrolling the “correct”
subjects in Ph II–III clinical trials – i.e.,
those who can show a therapeutic benefit
from the anti-infective therapy.
For example, while at Lederle
Labs, I worked on a new indica-
tion for MINOCIN®-namely, treatment
of moderate-to-severe periodontitis.
MINOCIN®-reduces the numbers of
the putative periodontal pathogens Acti-
nobacillus actinomycetemcomitans (Aa),
Prevotella intermedia (Pi), Porphyromonas
gingivalis (Pg), Tannerella forsythia, and
Treponema denticola [the latter three
organisms constitute red-complex bac-
teria (RCB)]. However, scaling and root
planing (S/P), the gold standard treatment
removes approximately 90% of plaque and
bacteria. We wanted to show increased
benefit in Ph II trials with adjunctive
use of microencapsulated minocycline
hydrochloride (ARESTIN®) plus S/P vs.
S/P alone. We needed a marker to identify
the “correct” patients to enroll.
We consulted four periodontologists
who had experience doing this research.
The first advised us to use a “clinical
marker” to identify active cases of peri-
odontitis. He recommended including sub-
jects with deep periodontal pockets – i.e.,
two teeth with at least one 7 mm pocket.
The trial produced trends, but no clear ben-
efit. The second recommended enrolling
subjects with two sites in the same quad-
rant with at least 7 mm pocket depth (PD).
The trial produced trends, but no clear ben-
efit. The third advised us to use a “micro-
biological marker.” Each subject had to
have one or more of the putative peri-
odontal. In addition, two teeth in the same
quadrant had to have at least 7 mm PD.
Again, we saw trends, but no clear ben-
efit. We discovered the vast majority of
sites (≥80%) were not actively breaking
down (the equivalent of a “burned out”
volcano). We needed sites that had active
tissue breakdown. Fortunately, the fourth
expert advised us to enroll subjects with
two teeth having one site each with PD
of at least 6 mm and with prostaglandin
E2 (PGE2) levels >66.2 ng/mL in gingi-
val crevicular fluid. PGE2 mediates inflam-
mation. An earlier study in 12 patients
with periodontal disease showed sub-
jects with periodontitis had high PGE2
levels (mean= 179.5 pg/µL) while sub-
jects with gingivitis had low PGE2 lev-
els (mean= 32.1 pg/µL) (1). We screened
400 subjects to find 50 subjects with high
PGE2 levels, but these subjects had peri-
odontal pockets like“active”volcanos). The
trial lasted 6 months duration and used a
formulation of minocycline microspheres
containing 1 mg minocycline. Finally, with
only 48 patients we showed an advantage
[clinically significant probing PD reduc-
tion, probing attachment level (AL) gain,
and reduction of pathogenic microflora]
with an antibiotic+ S/P vs. S/P alone (2).
Ph II an odyssey lasting several years
caused my management to ask “why are
you not in Ph III yet?” I replied: because
we don’t know if we have a drug. Only
after reviewing the data from the fourth
Ph II trial, did we believe we had a
drug.
The knowledge gained from these four
Ph II studies led to two identical piv-
otal Ph III safety and efficacy trials. A
total of 748 patients enrolled in both
studies. Patients had to have at least 10
teeth remaining in the function denti-
tion, excluding third molars, and at least
four teeth with periodontal PD of 6–
9 mm and bleeding on probing (BOP)
on all four qualifying teeth. In these
two adequate and well controlled stud-
ies, ARESTIN® plus scaling and root
planning showed a statistically significant
improvement in PD reduction when com-
pared to scaling and root planning alone at
9 months. These trials led to the approval
of ARESTIN®(3).
Similarly, in developing everninomycin,
a new class of intravenous antibacterial,
we wanted to take advantage of its low
MIC90 (0.2µg/mL) for Streptococcus pneu-
moniae. Consequently, my team designed
a Ph II community-acquired pneumonia
(CAP) trial targeting this organism. We
screened subjects and required a quality
sputum sample with a Gram stain showing
lancet-shaped, Gram-positive diplococci
(presumptive evidence of S. pneumoniae).
Sputum and blood cultures confirmed the
diagnosis. The two trials had three over-
lapping active dose groups and ceftriax-
one as comparator. We enrolled patients
simultaneously in RSA and Latin Amer-
ica to take advantage of the Austral
winter. To enroll 90 subjects in each
trial, we screened six subjects to find
one with a positive sputum Gram stain,
but it paid off. All arms in both trials
achieved >90% efficacy. However, devel-
opment of this drug ended due to safety
issues.
A prospective study of the diagnostic
utility of sputum Gram stain in pneumonia
(4) supports our methodology to identify
S. pneumoniae CAP cases; sputum Gram
stain had 0.82 sensitivity for Pneumococcal
pneumonia.
Finding patients with active periodon-
titis to enroll in our Ph II trials was more
challenging than anyone imagined. Nei-
ther a clinical marker, nor a microbio-
logical marker alone, or in combination
were sufficient. Only a clinical marker (PD)
in combination with an inflammatory
marker (elevated PGE2 levels) gave us the
patients who would benefit from adjunc-
tive treatment with ARESTIN®. Based on
this knowledge, a combination of a clinical
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marker (PD) and an inflammatory marker
(BOP) allowed us to enroll the correct
patients in Ph III.
Finding patients with CAP due to S.
pneumoniae was easier. We were only tar-
geting a bacterium. However, we still had
to pan for gold by using a sputum Gram
stain to enroll the correct patients.
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